Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A study looking at the long term follow up of people who have taken aspirin and esomeprazole to help prevent oesophageal cancer (AspECT Excel)
Cancer type:
Oesophageal cancer
Status:
Open
Phase:
Other
This study is looking at the long term benefits and risks of taking aspirin and esomeprazole to help prevent oesophageal cancer. It is a continuation of the AspECT trial.
It is open to people who took part in the AspECT trial.
Cancer Research UK supports this study.
More about this trial
The AspECT trial looked at aspirin and esomeprazole to see whether it could reduce the risk of oesophageal cancer for people with Barrett’s oesophagus.
In this trial there were 4 groups. It was a 
. People were put into one of the following at random:
- a low dose of esomeprazole and no aspirin
- a high dose of esomeprazole and no aspirin
- a low dose of esomeprazole and aspirin
- a high dose of esomeprazole and aspirin
The results of the AspECT trial showed that high doses of esomeprazole by itself reduced the risk of oesophageal cancer. It also showed that the combination of high dose of esomeprazole and aspirin might be better than high dose esomeprazole by itself.
In this study the team will look at your medical records over a long period of time.
The team think the results of this study could change the national guidelines about how best to prevent Barrett’s oesophagus developing into cancer.
The aims are to find out:
- how well the combination of high dose esomeprazole and aspirin works to prevent oesophageal cancer in the longer term
- more about the side effects
Who can enter
Who can take part
You may be able to join this study if you took part in the AspECT trial and you agree that the study team can look at your medical records.
Trial design
This is a phase 4 study. The team are looking at a maximum of 1,587 people to take part.
The study team will collect information from your medical and NHS records. This will include:
- personal information such as your date of birth
- information about your participation in the AspECT trial
- information about your health such as your Barrett’s oesophagus, other medical conditions, treatments and hospital visits
You don’t have any further treatment as part of this study.
Hospital visits
There are no hospital visits.
Side effects
There are no side effects.
Location
Aberystwyth
Chester
Croydon
Derby
Edinburgh
Glasgow
Gloucester
Harrogate
Kirkcaldy
Leicester
Liverpool
London
Nottingham
Portsmouth
Taunton
Torbay
Truro
West Bromwich
Yeovil
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
Chief Investigator
Dr Janusz Jankowski
Supported by
Cancer Research UK
University College London (UCL)
Other information
This is Cancer Research UK trial number is CRUK/21/020.
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
Last review date
CRUK internal database number:
19401
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
Over 60,000 cancer patients enrolled on clinical trials in the UK last year.
